205817-28-3

Upstream product

• 93250-97-6 (2R,4S)-methyl 4-benzyl-2-tert-butyl-3-formyloxazolidine-4-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 365402-94-4 (S)-(+)-2-amino-2-hydroxymethyl-3-phenylpropionic acid methyl ester 

Downstream Products

• 292035-12-2 (S)-2-((tert-butoxycarbonyl)amino)-3-hydroxy-2-benzylpropionic acid 
• 205817-31-8 C₂₀H₂₉N₃O₈ 
• 205817-29-4 (S)-2-(Benzyloxyamino-methyl)-2-tert-butoxycarbonylamino-3-phenyl-propionic acid methyl ester 

Relevant academic research and scientific papers

Synthesis of Easy-to-Functionalize Azabicycloalkane Scaffolds as Dipeptide Turn Mimics en Route to cRGD-Based Bioconjugates

In this paper we report the synthesis of new azabicycloalkane scaffolds, which could be exploited to obtain cRGD-based bioconjugates that may find promising application for targeted drug delivery, theranostic, and general cancer-cell labeling. By exploiti

α-Substituted quisqualic acid analogs: New metabotropic glutamate receptor group II selective antagonists

Syntheses of both the α-methyl and benzyl analogs of quisqualic acid are described. Testing of these compounds for their activity at excitatory amino acid receptors revealed a striking change in activity in comparison to quisqualic acid. This structural modification results in the loss of quisqualate's potent agonist action at both non-NMDA ionotropic glutamate receptors as well as at group I mGluRs, while allowing these analogs to acquire antagonist properties with relative selectivity for group II metabotropic glutamate receptors.